BSECompany Update▲ PositiveResults6d ago
Marksans Pharma Ltd
Press Release for Financial Results Q2FY27
Marksans Pharma Ltd reported Q2FY27 financial results, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore. H1FY27 revenue grew 32.9% to ₹1,781 crore, and PAT nearly doubled to ₹303 crore.
BSECompany Update▲ PositiveResults6d ago
NDR Auto Components Ltd
as per attachment.
NDR Auto Components Ltd has announced its Q2 and H1FY27 financial results, showing strong growth across key financial metrics. The company's total income, EBITDA, and PAT have increased by 11.2%, 11.1%, and 7.4% respectively on a year-over-year basis. The company has also expanded its order book and capacity, and has entered into a joint venture with DYA, a leading seat supplier to Hyundai & Kia in Korea.
NSEPress Release▲ PositiveResults6d ago
Marksans Pharma Limited
Press Release
Marksans Pharma Limited has reported its unaudited financial results for the quarter and half year ended September 30, 2026, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore.
NSEPress Release▲ PositiveResults6d ago
Rajshree Polypack Limited
Press Release
Rajshree Polypack Limited has announced its Q2 and H1 FY2027 financial results, with revenue from operations at ₹102.90 Crores and ₹205.81 Crores respectively, and operating EBITDA at ₹13.05 Crores and ₹27.47 Crores respectively. The company has maintained its operating margins despite a sharp rise in raw material prices and softer export demand. The results also highlight the resilience of the business, with a strong domestic revenue growth of 37.37% YoY in Q2 and a growth of 21.82% YoY in H1.
BSECompany Update▲ PositiveResults6d ago
Marksans Pharma Ltd
Investor Presentation Q2FY27
Marksans Pharma Ltd has announced its Q2FY27 financial results, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore.
NSEPress Release▲ PositiveJoint Venture6d ago
Ndr Auto Components Limited
Press Release
NDR Auto Components Limited has announced the formation of a joint venture with DYA Co., Ltd. to manufacture automotive seats in India for Kia India and Hyundai India. The joint venture will be incorporated in India, with NDR Auto Components holding 51% and DYA holding 49% of its share capital.
NSEInvestor Presentation▲ Positiveinvestor_presentations6d ago
Exide Industries Limited
Investor Presentation
Exide Industries Limited has informed the Exchange about Investor Presentation, highlighting its core business, new energy business, and innovation-led capabilities. The company has a strong presence in 70+ countries, serves 120,000+ touchpoints, and has a 100% share of business on key new models with large OEMs. Exide has a diversified and resilient lead-acid business, with a portfolio spanning 2.5Ah - 20,200Ah, and a brand built over nearly 8 decades. The company has a manufacturing base with 11 plants, including 2 plants of Exide Energy Solutions Limited (EESL) and 3 lead recycling plants of Chloride Metals Limited (CML). Exide has a strong R&D centre and has initiated commercial production of lithium-ion cells, packs, and modules.
BSECompany Update▲ PositiveJoint Venture6d ago
NDR Auto Components Ltd
as per attachment.
NDR Auto Components Ltd has announced the formation of a joint venture with Korea's DYA Co Ltd to manufacture automotive seats in India, with an investment of up to INR 62.96 crore. The joint venture will cater to Kia India and Hyundai India, and NDR Auto Components will hold 51% of the share capital.
BSECompany Update▲ PositiveResults6d ago
Exide Industries Ltd
Please find enclosed letter w.r.t. Press Release : H1 FY27 Revenue growth 18.9%, PAT growth 46.7%. Sustained momentum in Q2.
6 GWh of Lithium-ion Cell Gigafactory Commissioned.
Exide Industries Ltd reported H1 FY27 revenue growth of 18.9% and PAT growth of 46.7%, with a strong Q2 performance driven by healthy demand and cost optimisation initiatives.
NSEInvestor Presentation▲ PositiveResults6d ago
Marksans Pharma Limited
Investor Presentation
Marksans Pharma Limited has informed the Exchange about Investor Presentation for Q2FY27, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore.
NSEBagging/Receiving of orders/contracts▲ PositiveOrder Win6d ago
Aptech Limited
Bagging/Receiving of orders/contracts
Aptech Limited has received a work order from the State Government Body to conduct computer-based examinations, with an estimated contract value of Rs. 1.24 crore.
NSEPress Release▲ PositiveResults6d ago
Exide Industries Limited
Press Release
Exide Industries Limited has reported a 18.9% YoY growth in revenue and 46.7% YoY growth in PAT for H1 FY27, with a strong Q2 performance driven by healthy demand and cost optimisation initiatives.
BSEBoard Meeting▲ PositiveResults6d ago
Dr. Lal PathLabs Ltd
Attached
Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter and half year ended September 30, 2026, along with the declaration of a 2nd interim dividend of INR 5 per equity share. The company has also appointed Ms. Vasuta Agarwal as an Additional Director and approved further investments in its subsidiary company.
BSECompany Update▲ PositiveOrder Win6d ago
Aptech Ltd
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Aptech Ltd has received a work order from a State Government Body to conduct computer-based examinations, with an estimated contract value of Rs. 1.24 crore.
BSEResult▲ PositiveResults6d ago
Exide Industries Ltd
Please find enclosed letter w.r.t unaudited financial results for quarter and half year ended 30th September 2026.
Exide Industries Ltd reported unaudited financial results for Q2 and H1 FY27, with revenue growth of 18.9% and PAT growth of 46.7%. The company commissioned 6 GWh of Lithium-ion Cell Gigafactory.
NSEPress Release▲ PositiveResults6d ago
Biocon Limited
Press Release
Biocon Limited has announced its consolidated financial results for the quarter and half-year ended September 30, 2026, with a 2% YoY increase in consolidated operating revenue to Rs 4,389 crore and a 5% YoY increase in biopharma revenue to Rs 3,583 crore.
BSECompany Update▲ PositiveResults6d ago
Biocon Ltd
Press Release
Biocon Ltd announced its consolidated financial results for the quarter and half-year ended September 30, 2026, with a 2% YoY increase in consolidated operating revenue to Rs 4,389 crore and a 5% YoY increase in biopharma revenue to Rs 3,583 crore.
BSECompany Update▲ PositiveProduct Launch6d ago
JBM Auto Ltd
JBM Auto Limited has informed the exchange regarding a Press Release dated 4th November 2026
JBM Auto Ltd has announced the launch of its new electric city bus, ECOLIFE e12, at Singapore Urban Mobility Week 2026.
NSEPress Release▲ PositiveResults6d ago
Keystone Realtors Limited
Press Release
Keystone Realtors Limited has announced its unaudited financial results for Q2FY27, with highest ever quarterly pre-sales of INR 14.23 billion, up 84% YoY, and highest ever quarterly PAT of INR 1.01 billion.
BSECompany Update▲ PositiveResults6d ago
CL Educate Ltd
Intimation of Schedule of Analysts and Investors Earnings Call pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
CL Educate Ltd has announced its unaudited financial results for the quarter and half year ended September 30, 2026, with a 13.2% increase in EBITDA and a 289 bps expansion in EBITDA margin.